论文部分内容阅读
The standard first line chemotherapy with a platinum based doublet (gemcitabina, paclitaxel, docetaxel, vinorelbine) for advanced NSCLC patients with good performance status provides response-rates of 20%-40% and a median survival of 8-10 months.Maintenance therapy has been proposed in an attempt to improve the outcome.Maintenance is defined as prolongation of chemotherapy duration with the administration of additional drug cycles at the end of adefmed number of initial chemotherapy cycles in non progressing patients (pts with CR, PR or SD).Maintenance is continued for a defined number of cycles, either until evidence of progressive disease or significant toxicity.